企业摘要
季度业绩走势
营业收入
营业利润率
市场偏好度
※ 点击图表可查看该月份的AI分析信息。
营业收入
合并
单独
营业利润
合并
单独
净利润
合并
单独
财务信息
保存为Excel
该期间没有财务信息数据。
~
季度
决算
*单位基准小数点第四位以下的数值标记为'0/-0'
财务指标预测
※ 本预测值是基于历史数据的AI简单估算值，可能与实际业绩存在差异。
企业概况
截至2026年6月
Oncocross Co.,Ltd. has focused on developing an AI platform to improve the efficiency of new drug development, based on the recognition that new drug development is stagnating due to the long time, enormous research costs, and associated risks required by traditional drug development methods. The company was the first in Korea to develop and operate RAPTOR AI, which uses AI to analyze changes in gene expression data (transcriptome) following drug administration or disease onset and matches diseases with optimal treatments, and its main business is to use this platform to screen for the optimal indications or combination drugs and to discover promising therapeutic drugs and targets for diseases.
代表理事
김이랑, 강지훈 (각자대표)
成立日期
2015年6月22日
法人类型
韩国创业板
行业分类
Research and experimental development on physics, chemistry and biology
法人注册号
11011-5758333
营业执照号
482-86-00109
电话号码
02-867-9967
传真号码
028679968
公司地址
7 Beobwon-ro 11-gil, Songpa-gu, Seoul
产品与服务
评论